/RUBY
RUBY Stock - Rubius Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.06+2.70%
+$0.00 (+2.70%) • Dec 29
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.32
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.06
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RUBY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.06 – $0.06
TARGET (TP)$0.07
STOP LOSS$0.05
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.21
52W High$0.38
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-178,446,000 | $-194,616,000 | $-166,448,000 | $-169,601,000 | $-91,663,000 |
| Net Income | $-230,863,000 | $-188,824,000 | $-162,040,000 | $-160,463,000 | $-89,195,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.56 | $-2.15 | $-2.01 | $-2.04 | $-1.28 |
Company Overview
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
1
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish1 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 13th 2022 | Guggenheim | Downgrade | Neutral | - |
Earnings History & Surprises
RUBYBeat Rate
47%
Last 15 quarters
Avg Surprise
-0.7%
EPS vs Estimate
Beats / Misses
7/8
Last 12 quarters
Latest EPS
$-0.61
Q1 2023
EPS Surprise History
Q2 21
+5.6%
$-0.51vs$-0.54
Q3 21
-16.7%
$-0.56vs$-0.48
Q4 21
+1.8%
$-0.55vs$-0.56
Q1 22
-5.2%
$-0.61vs$-0.58
Q2 22
-1.8%
$-0.58vs$-0.57
Q3 22
+5.8%
$-0.49vs$-0.52
Q4 22
+11.9%
$-0.37vs$-0.42
Q1 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Feb 26, 2024 | — | — | — | — |
Q4 2023 | Nov 7, 2023 | — | — | — | — |
Q3 2023 | Aug 18, 2023 | — | — | — | — |
Q2 2023 | Jun 23, 2023 | $-0.34 | — | — | — |
Q1 2023 | Feb 24, 2023 | — | $-0.61 | — | — |
Q4 2022 | Nov 9, 2022 | $-0.42 | $-0.37 | +11.9% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.52 | $-0.49 | +5.8% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.57 | $-0.58 | -1.8% | ✗ MISS |
Q1 2022 | Feb 25, 2022 | $-0.58 | $-0.61 | -5.2% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.56 | $-0.55 | +1.8% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.48 | $-0.56 | -16.7% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.54 | $-0.51 | +5.6% | ✓ BEAT |
Q1 2021 | Feb 23, 2021 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q4 2020 | Nov 9, 2020 | $-0.50 | $-0.51 | -2.0% | ✗ MISS |
Q3 2020 | Aug 10, 2020 | $-0.54 | $-0.47 | +13.0% | ✓ BEAT |
Q2 2020 | May 11, 2020 | $-0.57 | $-0.60 | -5.3% | ✗ MISS |
Q1 2020 | Mar 12, 2020 | $-0.60 | $-0.56 | +6.7% | ✓ BEAT |
Q4 2019 | Nov 14, 2019 | $-0.53 | $-0.59 | -11.3% | ✗ MISS |
Q3 2019 | Aug 13, 2019 | $-0.46 | $-0.50 | -8.7% | ✗ MISS |
Q2 2019 | May 15, 2019 | $-0.38 | $-0.42 | -10.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about RUBY
What is RUBY's current stock price?
Rubius Therapeutics, Inc. (RUBY) is currently trading at $0.06 per share. The stock has moved +2.70% today.
What is the analyst price target for RUBY?
No analyst price targets are currently available for this stock.
What sector is Rubius Therapeutics, Inc. in?
Rubius Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RUBY's market cap?
Rubius Therapeutics, Inc. has a market capitalization of N/A, making it a small-cap company.
Does RUBY pay dividends?
No, Rubius Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPTO
Aptose Biosciences Inc.
$1.71
Mkt Cap: $0.0B
BVXV
BiondVax Pharmaceuticals Ltd.
$1.36
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
GMDA
Gamida Cell Ltd.
$0.03
Mkt Cap: $0.0B
GRTS
Gritstone bio, Inc.
$0.03
Mkt Cap: $0.0B
NBRVF
Nabriva Therapeutics plc
$0.00
Mkt Cap: $0.0B
NEUP
Neuphoria Therapeutics Inc.
$3.89
Mkt Cap: $0.0B
NSTG
NanoString Technologies, Inc.
$0.11
Mkt Cap: $0.0B
TCDA
Tricida, Inc.
$0.11
Mkt Cap: $0.0B
TECX
Tectonic Therapeutic, Inc.
$19.56
Mkt Cap: $0.4B
Explore stocks similar to RUBY for comparison